What is the appropriate prescribing regimen for modafinil in an adult with excessive daytime sleepiness (e.g., narcolepsy), including starting dose, titration, contraindications, and monitoring?

How to Prescribe Modafinil

Start modafinil at 200 mg orally once daily in the morning for narcolepsy or obstructive sleep apnea, taken as a single dose. 1

Approved Indications

Modafinil is FDA-approved and strongly recommended by the American Academy of Sleep Medicine (2021) for:

• Narcolepsy (STRONG recommendation) 2
• Idiopathic hypersomnia (STRONG recommendation) 2
• Obstructive sleep apnea (OSA) - for residual excessive daytime sleepiness despite adequate CPAP therapy 1
• Shift work disorder (SWD) 1

Dosing Regimen

Standard Dosing

• Narcolepsy/OSA: 200 mg once daily in the morning 1
• Shift work disorder: 200 mg once daily, taken approximately 1 hour before the start of the work shift 1

Dose Titration

• The 200 mg dose is the recommended starting and maintenance dose
• Doses up to 400 mg/day have been studied and are well-tolerated, but there is no consistent evidence of additional benefit beyond 200 mg/day 1
• If considering dose escalation to 400 mg for inadequate response, this can be given as a single morning dose 1
• For patients with residual late-day sleepiness on 400 mg once daily, a split-dose regimen (400 mg at 7 AM + 200 mg at noon) is more effective than 400 mg once daily 3

Special Populations

Severe Hepatic Impairment

• Reduce dose to 100 mg once daily (one-half the recommended dose) 1

Geriatric Patients

• Consider using lower doses (e.g., 100 mg) and monitor closely due to potential for decreased hepatic/renal function 1

Renal Impairment

• No specific dose adjustment required, but use caution as elimination half-life may be prolonged 4

Contraindications

Absolute contraindications:

• Known hypersensitivity to modafinil or armodafinil 1

Relative contraindications/cautions:

• Moderate to severe hypertension 4
• History of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia, or other cardiovascular disease - consider increased monitoring 1

Critical Safety Warnings

Serious Dermatologic Reactions (BLACK BOX-level concern)

• Discontinue immediately at the first sign of rash, unless clearly not drug-related 1
• Risk of Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS syndrome 1
• Median time to serious rash: 13 days 1
• Higher risk in pediatric patients (not approved for use in children) 1

Other Serious Reactions

• Angioedema and anaphylaxis: Discontinue if suspected 1
• Multi-organ hypersensitivity reactions: Discontinue if suspected (fever, rash, lymphadenopathy, organ dysfunction) 1

Psychiatric Symptoms

• Use caution in patients with history of psychosis, depression, or mania 1
• Monitor for new or worsening psychiatric symptoms
• Consider discontinuation if psychiatric symptoms develop 1

Monitoring Requirements

Baseline Assessment

• Confirm diagnosis with objective sleep testing (polysomnography, Multiple Sleep Latency Test)
• Screen for cardiovascular disease, hypertension
• Assess psychiatric history
• Pregnancy test in women of childbearing potential
• Baseline blood pressure and heart rate

Ongoing Monitoring

• Assess degree of sleepiness frequently - patients may still have residual sleepiness requiring activity restrictions 1
• Blood pressure and heart rate at follow-up visits
• Monitor for rash, especially in first 2-3 weeks
• Assess for psychiatric symptoms
• Evaluate treatment response using validated scales (Epworth Sleepiness Scale, clinical global impression)

Drug Interactions

Hormonal Contraceptives

• Modafinil reduces effectiveness of ethinyl estradiol-containing contraceptives 1
• Use alternative or additional barrier contraception during treatment and for 1 month after discontinuation 1

CYP450 Interactions

• CYP2C19 substrates (omeprazole, phenytoin, diazepam): Modafinil may increase exposure - monitor and consider dose reduction 1
• Cyclosporine: Blood concentrations may be reduced - monitor levels closely 1
• CYP3A4 substrates: Modafinil is a weak inducer - may reduce levels of some medications

Clinical Efficacy Evidence

Multiple high-quality RCTs demonstrate that modafinil:

• Significantly improves objective wakefulness on Maintenance of Wakefulness Test (mean increase 2.95-3.56 minutes) 5, 6
• Reduces subjective sleepiness on Epworth Sleepiness Scale (mean reduction 3.34 points) 6
• Improves executive function and cognitive performance 3
• Does not affect nighttime sleep architecture or ability to nap voluntarily 7, 8
• Maintains efficacy without tolerance development for up to 40 weeks 9, 4

Common Adverse Effects (≥5%)

• Headache (most common - 51-52% vs 36% placebo) 4
• Nausea
• Nervousness/anxiety (RR 3.08) 5
• Insomnia (RR 4.64) 5
• Rhinitis
• Diarrhea
• Back pain
• Dizziness
• Dyspepsia

Treatment discontinuation due to adverse events occurs in 2.5 times more patients on modafinil vs placebo 5

Key Clinical Pitfalls to Avoid

1. Do not use modafinil as monotherapy for OSA - it treats sleepiness but not the underlying airway obstruction. Maximize CPAP therapy first 1

2. Do not assume patients are fully alert - residual sleepiness may persist. Counsel patients about driving and operating machinery risks 1

3. Do not overlook contraceptive counseling - failure to address this leads to unintended pregnancies 1

4. Do not continue if rash develops - serious dermatologic reactions can be life-threatening 1

5. Do not expect cataplexy improvement - modafinil does not suppress cataplexy in narcolepsy patients 9, 4, 10

6. Do not abruptly stop after long-term use - while withdrawal syndrome is rare, patients will experience return of baseline sleepiness 7

Controlled Substance Status

• Schedule IV controlled substance (C-IV) 1
• Low abuse potential compared to amphetamines 7, 4
• No evidence of withdrawal syndrome or rebound hypersomnia upon discontinuation 7, 9